Get the Stockscreener App
30.17
3.15%
-0.98
After Hours:
30.17
Ionis Pharmaceuticals Inc stock is traded at $30.17, with a volume of 2.04M.
It is down -3.15% in the last 24 hours and down -9.10% over the past month.
See More
Previous Close:
$31.15
Open:
$30.24
24h Volume:
2.04M
Relative Volume:
1.33
Market Cap:
$5.01B
Revenue:
$705.14M
Net Income/Loss:
$-453.90M
P/E Ratio:
-9.9243
EPS:
-3.04
Net Cash Flow:
$-551.29M
1W Performance:
-9.81%
1M Performance:
-9.10%
6M Performance:
-24.69%
1Y Performance:
-30.40%
1-Day Range:
$29.61
$30.48
1-Week Range:
$29.61
$33.76
52-Week Range:
$29.61
$52.34
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Name
Ionis Pharmaceuticals Inc
Sector
Industry
Phone
(760) 931-9200
Address
2855 GAZELLE COURT, CARLSBAD, CA
Compare IONS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
30.17 | 5.01B | 705.14M | -453.90M | -551.29M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-02-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jul-24-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-16-24 | Resumed | Jefferies | Buy |
| Jun-14-24 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Apr-10-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-02-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-23-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Sep-29-23 | Initiated | Raymond James | Strong Buy |
| Jul-31-23 | Upgrade | Citigroup | Neutral → Buy |
| Jun-07-23 | Resumed | Piper Sandler | Overweight |
| May-04-23 | Upgrade | Citigroup | Sell → Neutral |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Dec-21-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-09-22 | Resumed | Morgan Stanley | Overweight |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Mar-31-22 | Resumed | Piper Sandler | Overweight |
| Mar-01-22 | Initiated | Citigroup | Sell |
| Mar-01-22 | Initiated | Guggenheim | Buy |
| Feb-01-22 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-14-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| May-07-21 | Upgrade | UBS | Sell → Neutral |
| Mar-01-21 | Upgrade | Barclays | Underweight → Equal Weight |
| Dec-16-20 | Initiated | UBS | Sell |
| Dec-15-20 | Upgrade | Cowen | Market Perform → Outperform |
| Sep-14-20 | Resumed | JP Morgan | Neutral |
| Sep-02-20 | Initiated | The Benchmark Company | Hold |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Initiated | Oppenheimer | Outperform |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| Nov-07-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Sep-10-19 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Aug-08-18 | Reiterated | Stifel | Hold |
| Aug-07-18 | Reiterated | Stifel | Hold |
| May-08-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-06-17 | Resumed | Goldman | Sell |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Aug-09-17 | Reiterated | Stifel | Hold |
| Mar-10-17 | Downgrade | Goldman | Neutral → Sell |
| Dec-28-16 | Reiterated | BMO Capital Markets | Outperform |
| Dec-27-16 | Reiterated | Leerink Partners | Mkt Perform |
View All
Ionis Pharmaceuticals Inc Stock (IONS) Latest News
Assessing Ionis Pharmaceuticals: Insights From 8 Financial Analysts - Benzinga
Redburn Atlantic Initiates Ionis Pharmaceuticals at Neutral With $39 Price Target - MarketScreener
Ionis to present at upcoming investor conferences - The Joplin Globe
Ionis Secures Triple Conference Spotlight: Key Investor Events Announced for Spring 2025 - Stock Titan
Redburn initiates Ionis stock with Neutral, sets $39 target - Investing.com India
11 Best Gene Therapy Stocks to Buy According to Analysts - Insider Monkey
IONS Out-Licenses ex-U.S. Rights for Rare Disease Drug Tryngolza to Sobi - MSN
Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S. - MSN
Catalyst (CPRX) Up 14.7% Since Last Earnings Report: Can It Continue? - Yahoo Finance
RNA Biotechs: Current State And Outlook - Seeking Alpha
Ionis and Sobi agree on olezarsen commercialisation - Yahoo
Ionis licenses olezarsen to Sobi for global reach By Investing.com - Investing.com South Africa
Ionis Partners With Sobi to Commercialize Familial Chylomicronemia Syndrome Treatment Outside US - Marketscreener.com
Ionis Expands Partnership With SOBI To Include Olezarsen Commercialization Outside The U.S. - Marketscreener.com
Ionis licenses olezarsen to Sobi for global reach - Investing.com
First-Ever FCS Treatment: Ionis Expands Global Reach with Major Partnership Deal - Stock Titan
Is Ionis Pharmaceuticals, Inc. (IONS) a Promising Biotech Stock According to Wall Street Analysts - Insider Monkey
12 Most Promising Biotech Stocks According to Wall Street Analysts - Insider Monkey
Ionis Pharmaceuticals’ SWOT analysis: RNA pioneer’s stock faces pivotal year - Investing.com
Ionis Rings the Opening Bell - Nasdaq
Ionis Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting - GlobeNewswire Inc.
Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S - simplywall.st
Why Is Ionis Pharmaceuticals (IONS) Up 0.1% Since Last Earnings Report? - Yahoo Finance Australia
Multiple System Atrophy Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma, Ionis Pharma - Barchart
Multiple System Atrophy Market to Reach New Heights in Growth - openPR
Familial Chylomicronemia Syndrome Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Spinocerebellar Ataxias Pipeline 2025: Therapies, MOA - openPR
Ionis Pharmaceuticals at UBS Virtual CNS Day: Neurology Pipeline Insights By Investing.com - Investing.com UK
Opinion: Angelman Syndrome Race Heats Up Among Ionis, Ultragenyx and Neuren - BioSpace
IONS/AZN Get FDA Nod for Amyloidosis Drug, Wainzua in Europe - MSN
Retinitis Pigmentosa Pipeline 2024: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Biogen, Neurotech, Ionis Pharma, Nacuity Pharma, Allegro Ophthalmics - Barchart
Ionis Pharmaceuticals CEO Monia sells $4,524 in stock By Investing.com - Investing.com Australia
Charles Schwab Investment Management Inc. Purchases 38,420 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - Defense World
Chief Executive Officer Monia Brett P sold $4,525 worth of shares (140 units at $32.32), decreasing direct ownership by 0.08% to 180,980 units (SEC Form 4) - Quantisnow
Ionis Pharmaceuticals CEO Monia sells $4,524 in stock - Investing.com India
Ionis Gets Tryngolza Launch Cash From Ono Via Sapablursen License - Citeline
Ionis Pharmaceuticals at Barclays Conference: Strategic Growth and Partnerships By Investing.com - Investing.com UK
Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases - AOL
Ono earmarks $940m to gain rare blood cancer therapy from Ionis - Yahoo
Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal - AOL
Ono partners with Ionis for sapablursen - The Pharma Letter
Ono pays $280M to license Ionis rare disease drug - BioPharma Dive
Oppenheimer maintains Outperform on Ionis, $78 target By Investing.com - Investing.com UK
Ionis out licenses blood disorder therapy to Ono in a deal worth up to $940M - MSN
Ionis Out-Licenses Rights for Rare Blood Cancer Drug to Ono - Zacks Investment Research
Ionis Pharmaceuticals Enters Global License Agreement With Ono Pharmaceutical for Sapablursen - Marketscreener.com
Jones Financial Companies Lllp Has $326,000 Stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - Defense World
Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Cut to $47.00 by Analysts at JPMorgan Chase & Co. - Defense World
Ionis Pharmaceuticals Inc Stock (IONS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.05%
1.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):